# UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.: Phase 1 study started recruiting, 30 planned (Bladder (Urothelial, Transitional Cell) Cancer, NMIBC)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC |
| NCT ID | NCT07725796 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Bladder (Urothelial, Transitional Cell) Cancer; NMIBC; Urothelial Carcinoma Bladder; Urothelial Carcinoma in Situ; Urothelial Carcinoma Recurrent; Urothelial Carcinoma of the Urinary Bladder |
| Intervention types | biological |
| Target enrollment | 30 |
| Site countries | United States |
| Posted | 2026-07-24 |
| Planned start | 2026-09-28 |
| Event | Started recruiting |
| Event date | 2026-09-28 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07725796). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.